# A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)

> **NCT04305184** · PHASE1,PHASE2 · TERMINATED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Chronic Tympanic Membrane Perforation

## Interventions

- **DRUG:** ASP0598
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04305184
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-10
- **Primary completion:** 2023-01-24
- **Final completion:** 2023-01-24
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Lack of Efficacy
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305184, "A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04305184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*